Bionano Genomics
BNGO
53 hedge funds and large institutions have $4.48M invested in Bionano Genomics in 2024 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 14 closing their positions.
177% more call options, than puts
Call options by funds: $166K | Put options by funds: $60K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.32% more ownership
Funds ownership: 9.25% → 9.56% (+0.32%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
4% less funds holding
Funds holding: 55 → 53 (-2)
20% less capital invested
Capital invested by funds: $5.61M → $4.48M (-$1.13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.54M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$486K |
| 3 |
BlackRock
New York
|
+$204K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$181K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$610K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$220K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$108K |
| 4 |
Jane Street
New York
|
-$100K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$97.2K |
BNGO Hedge Fund Activity: Q2 2024 in Review
53 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q2 2024, worth a combined $4.48M — down 20% from $5.61M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BNGO positions and 14 closed out — a net gain of 1 holder — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.54M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $610K sold.
- 53 institutional investors held Bionano Genomics (BNGO) as of Q2 2024, down from 55 in Q1 2024.
- Funds reported $4.48M of Bionano Genomics stock for Q2 2024, down 20% quarter-over-quarter.
- 15 funds opened new Bionano Genomics positions in Q2 2024 and 14 closed out, a net change of +1 holder.
- The largest Bionano Genomics buyer in Q2 2024 was Armistice Capital, an estimated $1.54M added.
- The largest Bionano Genomics seller in Q2 2024 was GSA Capital Partners, an estimated $610K sold.
Based on aggregated 13F filings for Q2 2024.